But $NVS' earnings outgrew $MRK's in the first quarter, rising 29%. $PFE income fell 6%.

In the second quarter, analysts expect Merck to earn $1.08 per share on $10.84 billion in sales. On a year-over-year basis, earnings would slide 17% and sales would dip 7.8%.